Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
chapter 11 of filing for banktupcy is a very simple basic process.
creditors force you to sell all assets that you own. if the proceeds is less than that is owed. it's the creditors problem
after chapter 11 the corporation or person has no debts. and is cleared.
that is how bankruptcy chapter 11 works. after all the assets are sold any if any money is paid to the creditors, in this case, there is no money to pay anyone. less than 1 million so that 40 million 'fake liability' against the assets get nothing as all the money is in some 'trust' fund. funds in at trust are impossible to get out without the approval of the trustee. trust fund have a charter saying how the money is paid out too. but that is if the trustee can be trusted. lots of trust funds, the trustee bills the trust fund like percentage of value of assets or annual 'management fee' and sometimes the management fee is so high after a few years, there is no money in the fund. there is less than $500,000 in the fund if the trustee is billing the fund $200,000/year, plus trust fund expenses all the money is gone in a year.
what don't you understand,
the hgenq corporation sold all it's ip assets for nothing.
hgenq has been in DIP debtor in possession means the creditors have seized all assets and auctioned it off to REPAY 'creditor claims' whether those 'disputed' creditor claims are valid was not disputed by hgenq.
and no need to dispute any disputed claim since the creditors get nothing as their is nothing to repay them of any claims they claim. the law suite for the .046/share settlement they are in the same line as the 100 other fake creditor claims.
I don't know what you're talking about, but neither do you. And you're certainly not in position to determine the validity of the claims against the company. The chief invalid claim is that the ACTIV-5 trial did not corroborate the results of the LIVE-AIR trial. The truth is, the ACTIV-5 trial was designed to fail, and failure to meet the endpoint of that trial of late-stage patients, had nothing to do with the successful treatment of the early-stage LIVE-AIR patients. And the class action tort lawyers who brought suit against the company were totally derelict in their duty.
Your reply failed to address the issue I presented in my post. What does that information mean to you?
My concern was in regards to the Liquidation Trustee having sole discretion to declare a distribution to existing equity holders. It seems to me that Humanigen management shares that concern, and their objection still appears to be on tomorrow's docket. I think they intend to safeguard claims of equity interest accounts, not only on shareholders' behalf, but on Humanigen's behalf, as well, since I think they control ~90% of our Outstanding Shares.
https://document.epiq11.com/document/getdocumentbycode?docId=4343828&projectCode=HUM&source=DM
FDA approves Merck pneumococcal disease vaccine designed for adults https://www.cnbc.com/2024/06/17/fda-approves-merck-pneumococcal-disease-vaccine-designed-for-adults.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
to defend yourself against fake creditor claims would cost additional legal fees and that is itself a legal harassment with false accusations with false claims. In many countries making false charges or lawsuits is illegal. it's considered legal harassment. Trump trial is common political persecution with fake charges and fake blown charges for political gains. the charges or claims of crime or harm by complainant is obviously unreasonable and bogus. and penalty doesn't meet the punishment or fine doesn't justify the CRIME or monetary, or harm the complainant received. that is the symbolism of the lady wearing blind around here eyes and weighs the harm and punishment to carry out justice, an eye for an eye. or the PUNISHMENT must equal the HARM done. or using the balance scale of justice. your weigh the harm or real harm and give a sentence. that is 'reasonable' and 'fair' without biases or prejudice. or the law is blind
in most cases, it's much easier to just declare chapter 11 or bankruptcy for man companies or individuals than object to fake creditor claims.
in bankruptcy, some people just sell all their assets before declaring bankruptcy or transfer all assets to another country then go to court to dispute fake claims like 100 million dollar fine for 'defamation' in social media CRIME. the judge who gave the $100 million fine knows the fine was just a token that the accused is guilty and complainant won't get a dime of her 'complaint' that she was wronged or harm in CIVIL COURT and get this clown case out of he court and stop wasting the gov't and judge time is this bogus trial.
"Docket # 254
Filed May 03 2024
First Omnibus Objection to Claims //Debtor's First Omnibus Objection (Non-Substantive) to Claims on Account of Equity Interests. Filed by Humanigen, Inc.. Hearing scheduled for 6/13/2024 at 10:00 AM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #1, Wilmington, Delaware. Objections due by 5/17/2024. (Attachments: # (1) Notice # (2) Exhibit 1 # (3) Exhibit 2) (Forshay, Shannon)
Case Number 24-10003 Humanigen, Inc."
4th tab
https://dm.epiq11.com/case/humanigen/dockets
Always best to remain up to date. But prior to the years I spent here, I spent years in another company, where the SEC totally abused their discretionary authority, as they likely did here, and as NIAID/NIH, and the FDA definitely did. And the much more extensive research I did in the other company showed just cause to a judge to grant me subpoena power, which I used. So time I don't have to spend in the weeds, because of research from people like you, is very much appreciated.
So I assume the Omnibus Hearing and the Governmental Bar Date, whatever those are, are likewise delayed.
Like I see you did, I credited US-JUSTICE for his valid points, but he then tends to get sidewise in keeping with what I suspect is his agenda, and it only diminishes whatever credibility he had. The government's abuse of discretionary authority is one thing, when the SEC uses it to fund recipients of government largesse from the Treasury Dept. The abuse of discretionary authority by NIAID, the NIH, and the FDA, causes the preventable loss of life, and that is a worthy cause to fight.
This is the first post I have read from you with a legitimate substance to it surrounding the company and the stock. Unfortunately, you had to do it while also being rude to another person....which I honestly just don't understand.
Anyway, I believe you are correct about the hearing date change which can be seen at the site I posted. I had not mentioned the postponement prior because the only place that actually said those words was the Delaware bankruptcy court calendar page which stopped working for our presiding judge within hours of the alteration (go figure) and I hadn't taken a screenshot.
Thank Jay.
I've been a long-time stockholder and board reader prior to posting, and have done my due diligence and best to remain up to date.
I really appreciate when other stockholders, such as SorcererGuru44, contribute valuable research. I've been following this company since 2015, invested since it became Humanigen in 2017, and I have previously said that I have had my fill of legal boilerplate. I'll take the CliffNotes version, with links, anytime.
https://dm.epiq11.com/case/humanigen/dockets
Cowtown is either paid troll or stock 'cheerleader' . because if he was that dedicated and did his 'homework' and due diligence to this ticker he would know that the hearing for june the 13 was cancelled and postponed to june 18,2024
the guy would not waste time reading the over 300 documents. which 3/4 of it's just adminstrative filings that nobody reads it. only 10 documents is of any relevancy to this case.
hgenq as a BANKRUPT company somehow spent over 3 million in the last two years in legal fees and company has only 4 employees.
you be surprise who many people would just buy $20,000 of a stock and don't even read the SEC reports of a company and call that an 'investment' people spend more time shopping around for a $300 air conditioner than a $10,000 investment
I wish there was news. I've been wishing for news ever since we filed our topline data from the LIVE-AIR trial in March of 2021, just one year after covid hit our shores. That was an incredible achievement, especially for a small-cap biotech. Lenz could have saved the lives of many who were lost; it could have improved the quality of life in patients that couldn't be saved; and it could also have improved the quality of life of those of us who invested here. I think management is steadfast in their effort to achieve success, and I owe them support in their quest.
6/13 has come and gone where's this "news"?
That's actually good to know, SorcererGuru44. Sanofi may not be quite ready to spinoff until next quarter, which, as you said, "...may or may not mean anything to us."
Appreciate your research.
I have only found information regarding Dundon Advisers becoming the liquidating trustee in one other chapter 11 liquidation case.
I believe there are at least a few more, I just cannot find additional info on them. The one I am able to research is still in business, they are still the liquidating trustee, and they seem to be doing alright - at least based on the minimal filings I was able to review from the past few months.
That may or may not mean anything to us. Just interesting to point out.
Management dutifully reported the clinical safety and efficacy results of lenz in treating/preventing CMML in the PREACH-M study, as well as the outstanding Hazard Ratio of 2.54, as determined by the Thorax peer review of the LIVE-AIR trial for covid.
The IP was devalued by the NIAID/NIH ACTIV-5/BET-B trial design and orchestrated results.
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Receives-Preliminary-Topline-Data-From-NIHNIAID-Study-of-Lenzilumab-in-ACTIV-5BET-B/default.aspx
So the issue is not my claiming an overstated value of the IP in the billions. That was, is, and will be the value.
You have shown no interest in the real issue that decimated the value of this life-saving therapeutic, nor in the willful/criminal negligence of the NIAID/NIH and FDA, which continues to permit the preventable loss of life. I don't understand why you wouldn't want to give this issue serious attention, and quit wasting your ability.
Before the 1930's, most policing was the city level. there was no FBI for federal crimes. and no SEC, SEC has failed Americans in such things as investment fraud as crimes in the market and exchange requires expertise in the inudstry. And it's easier to corrupt local judges and police than some out of state agency like the FBI as FBI staff changes all the time and much bigger unlike local police or local judges. Even the hiring and appointment of judges in the local level is corrupt or nepotism or based on 'loyalty' rather than credentials and much easier to corrupt or bribe local gov't than federal gov't
Board of directors fudiciary failure like the board of directors in Tesla actually 'approved' paying Elon 45 billion salary because if they don't he'll quit.?
the board of directors were forced or bribed to vote yes. to elons 45 billion. now this is in very high profile real company not a penny stock, now if these people can be that corrupt in tesla and run the company like some penny stock... they even got the media outlets all bribed to not critize elon's corporate embezzlement of 45 billion as not illegal or wrong.
The fact is the ip asset you claim to be worth billions or worth anything was sold for nothing or zero value in a rigged auction. nobody could be for it. and the company didn't solicit any bids in the 6 months it claimed to have marketed the assets to interested buyers.
I actually believe that our likelihood of success is MORE realistic now than it has ever been. Sanofi is a behemoth, and 100% capable of meeting all of our manufacturing and other CMC requirements. Even more, they have 77 projects in their active pipeline, to include therapeutic development for:
Immunology & Inflammation
Neurology
Oncology, and
Rare Diseases
I think lenz could be market-dominant in all these areas.
So there are numerous opportunities for lenz to enhance or replace the therapeutics that are already in these many clinical trials. Some of these trials are for the same indications that lenz, and Ifab, are already being developed for, such as AML, (CMML for us) GvHD, and solid tumors.
https://www.sanofi.com/en/our-science/our-pipeline
And I'm hoping that Dubovsky can help us capture foreign regulatory approval and commercialization of lenz for covid through the vast network Novavax has worldwide. In fact, Novavax is current with domestic competitors for the 2024-2025 vaccine year, and they will again have the only non-mRNA vaccine in the US.
So when the Milestone Events were amended to be significantly expanded, I think much of this increased opportunity will stem from our role in the Sanofi/Novavax entity that will follow Sanofi's spinoff.
I eagerly await a Press Release in these matters, and I look forward to the recall of our loaned shares
“If overseas traders who are aware of the potential for Lenz approval aren’t trying to sell shares, it kinda tells you all ya need to know? “
Not really the same thing, you have a sell order in place that is way above any
Pps level else we have seen in years. It’s not going to fill in the state that HGENQ is in right now. I could put in a sell order for .05 tomorrow and it won’t fill, no one will buy those shares for even a nickel at this point,
Those who aren’t selling like myself see it as a wasted chance at a gamble that may play out, the old saying of “a chip and a chair” and know it’s pointless to sell at this point anyway.
As always I like your optimism, finding less realistic at this point but crazier things have happened.
I did sell nearly a million ALPP shares at .06 to buy more HGEN during COVID…ALPP ran to $9.00 shortly there after….Durrant owes me a mulligan haha!
That looks like it leans in Jay's direction.
Liquidating trustee is Dundon Advisers LLC, which incidentally specialize is restructuring.
"If overseas traders who are aware of the potential for Lenz approval aren’t trying to buy shares, it kinda tells you all ya need to know."
Doesn't that logic equally apply to sellers, such that:
If overseas traders who are aware of the potential for Lenz approval aren’t trying to sell shares, it kinda tells you all ya need to know?
I don't think that investor sentiment can adequately be reflected on the Expert Market, where Bid/Ask information is not displayed.
I don't want to downplay the situation we are now in, which is being placed in liquidation status, versus reorganization status. I don't know who the Liquidating Trustee is. No do I know if this is a management-supported defensive tactic. But I don't accept that he has unfettered authority to use "sole discretion," as is reported. An offer of Taran shares, for HGEN shares, for example, should prompt the judge to disallow liquidation. And more, the announcement of regulatory approval of lenz to treat or prevent CMML and/or aGvHD, should result in more than enough funds for management to fully meet obligations to the Unsecured Creditors, and result in the discharge of this case from the bankruptcy court.
Anything less than a distribution to existing equity holders, this close to our success, would transcend a mere travesty of justice. It would be illegal under the circumstances I just described.
as for the stock one guy still owns 110 million shares of some worthless shares. he needs the chapter 11 to conclude and hot ip assets to be sold and liquidated and shares of hgenq shares cancelled and dissolved before he sells his 110 million shares.
banning americans from buying stock but allow foreigners to buy the stock due to regulations.
but if americans can still buy the stock if they know someone in another country and do OTC contract or swap to buy the stock on their behalf. it has to do with SEC regulations which apply only to american brokerage/dealer accounts not foreign brokerage/dealer accounts.
any american can just open LLC account in some foreign brokerage account and buy these shares, but why.?
I guess foreigners have much more difficult in sueing an american company or american and file civil or criminal charges.
It much harder for a foreigner to sue an american, you have to be physically in court to file the charges. but much easier for an american to sue another american in civil court that is why SEC bans Americans from buying these stocks.
if you wired money to some country in another country it's next to impossble to get the money back, but if the person resides in US and money is still in the country, you can still get it back with lawsuit etc. but if the person is another country, the cops in another country won't even answer your emails that you got ripped off.
finally some common sense
I honestly feel that if there was anything left here, if there were any chance of recovery for commons we wouldn’t be trading at these levels. HGEN and Lenz are known overseas, no chance that traders overseas who see this as a viable play for any returns wouldn’t be trying to buy shares that US traders are excluded from buying.
If overseas traders who are aware of the potential for Lenz approval aren’t trying to buy shares, it kinda tells you all ya need to know. This will be great for Tarran and Durrant, even Dale, for commons in HGENQ, I think it’s done and on its way to getting revoked.
Thank you for the link, SG44. So, it appears that there will be an Omnibus Hearing on Tuesday, and the Governmental Bar Date is set the day before my open sell orders expire on July 2. I don't want to see those orders expire.
I really don't know what that means, and I would much rather see those actions mooted by whatever course of action management might be implementing. But I will say that I continue to sense, everyday, that management is working with Sanofi on their spin-off, and that we could be looking at a partnership with Novavax in association with the Sanofi spin-off.
one of the main reasons companies and individuals hide their assets in swiss banks and cayman islands is not to hide ill gotten gains or hide money and not pay taxes,
the main reason people hide their assets under various corporations is to prevent easy access to funds from fake gov't fines and gov't confiscation and fake lawsuits and fake creditor claims. fake creditors who claim you owe them money or millions can be used as means of 'extortion' like guilliiani where some women claim he sexually harassed and judge gives here 100 million settlement and he was forced to declare bankruptcy.? he should object to such obscene and unfair fines order by anyone. the punishment doesn't fit the 'alledged' harm. it's like getting a 1 million dollar fine for speeding ticket or lying on your loan application due to technicalities. or lyaing about your net worth on some loan application when it's the job of the bank claims to be 'defrauded' when most loans are given based on credit checks etc. and it's the bank's problem if borrowere defaults on loan, not the gov't problem.
in bankruptcy court, the court ASSUMES all the FAKE creditor claims are true if the debtor doesn't OBJECT to the claims.
okay. and the debtor doesn't seem to object to the fake creditor claims because it wants to get sued and auction off the ip assets for free since the debtor is also the only bidder and owns Taran.
if feel you've been ripped as an investor, don't waste time with complaining to SEC which normally just sends a warning letter to the corporate head office which is now just an post office in a shared office and only receiving mail. if the company is dissolved case closed and SEC won't waste time with it, the company is dead if dissolved and legally you cannot put a dead man in prison.
alternative is criminal case
that is where the case goes to criminal charges by FBI or FTC.
if they cannot get an CRIMINAL conviction due to lack of evidence or nobody bother filing a criminal charge for larceny or fraud. and conviction, people go to prison. for like 4 years like Trump for lying on his loan application. or insider trading and front running, market manipulation etc which were made FELONY crimes by the gov't
then next step is CIVIl COURT. usually people found guilty of wrong doings or FRAUD don't go to prison and just pay a fine to the complainant, it's like divorce settlement in people's court. it's not a violent crime like armed robbery. etc
I certainly believe in Lenzilumab, we are both in heavy agreement with everything you shared.
My post is purely based on the asset disclosure that was filed, which of course does not include Lenzilumab as it has been sold to Taran. If management truly is doing something clever to help out shareholders that would be incredible, and I hope it is the case. My current viewpoint, despite being unfortunate, is only based on what I can read in the mass amount of filings I've reviewed.
I've still got my fingers crossed. I'm fairly certain we'll find out rather soon.
In any event, here is the link I promised to share where all dockets can be pulled: https://dm.epiq11.com/case/humanigen/info
I'm fully aware that the SEC has sealed the records in their case against Dale's entities, and I hope he prevailed in the Court of Appeals. I mean, really, management spelled out their share structure, to include the use of company insiders as nominee account holders, in an SEC filing. I knew as soon as I read the filing what they were doing, and why they were doing it. It was because management knew that the SEC would not protect them, and they had to have a plan to defend themselves, which they did very well.
"Based on the asset disclosure it doesn't appear there is nearly enough $ to reach us."
I think lenzilumab may prove to be the biggest blockbuster drug ever to hit the market. That is not a new conclusion, nor is it based on news that management has kept under wraps. Lenzilumab's astounding safety and efficacy was duly reported in the topline data of their LIVE-AIR trial, which showed a Hazard Ratio of 1.54, which was a 54% improvement over standard of care.
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Reports-Positive-Phase-3-Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventila-O9C2T.pdf
Just based on the release of the topline data, with the 54% improvement over placebo and standard of care, the market reacted so favorably that I was able to sell shares for as much as $27.78 and $29.07 on March 29, 2021.
"Highlights over the past year include:
Lenzilumab in COVID-19 patients
Completed the LIVE-AIR study, which showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for invasive mechanical ventilation compared with patients receiving standard of care and placebo.
Positive results of the LIVE-AIR study were published in The Lancet Respiratory Medicine, https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext. The Lancet publication concluded that lenzilumab treatment of patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile comparable to placebo..."
https://www.sec.gov/Archives/edgar/data/1293310/000121465922003320/ex99_1.htm
Here again, we see management reporting the peer-reviewed results published in Lancet. But in addition to the topline data, and the Lancet peer-review, the company reported the publication of a second peer-review in Thorax. This was on using CRP as a biomarker, and it showed that the early use of lenz in hospitalized and hypoxic covid pneumonia patients showed that "... baseline CRP <150 mg/L (HR: 2.54; 95% CI 1.46 to 4.41; p=0.0009)."
https://thorax.bmj.com/content/78/6/606
Personally, I think our market has greatly expanded to include treatment of non-hospitalized covid pneumonia patients. I base this on the Thorax peer review, which concluded:
"Exploratory analysis for the effect of lenzilumab on SWOV was conducted by the CRP baseline quartile. Response to lenzilumab was observed in the first through third quartiles of baseline CRP with the greatest lenzilumab treatment effect observed in the first quartile (CRP <41 mg/L; HR: 8.20; 95% CI 1.74 to 38.69; p=0.0079)." (Info is in paragraph just above Table 3).
We're seeing reports now that Pfizer and Moderna provide 70 - 80% of the FDA's operating revenue, and that NIH and NIAID scientists are receiving royalties from these manufacturers. Here is four year old data from the FDA acknowledging this practice.
"About 55 percent, or $3.2 billion, of FDA’s budget
is provided by federal budget authorization. The
remaining 45 percent, or $2.7 billion, is paid for
by industry user fees."
https://www.fda.gov/media/143704/download#:~:text=authorization%20funds%20about%2062%20percent,%40fda.hhs.gov.
That's why lenz, with an 8-fold improvement in treatment outcomes, when administered early to patients with CRP levels <41 mg/L, can't get regulatory approval, and consequently, millions of covid patients have, or will, suffer preventable deaths. This collusion and graft is what happens when executive agency bureaucrats have "discretionary authority," which I think should be rescinded.
Lenz was intended as a cancer drug before covid came along, and an effective CMML cancer drug is what lenz has proven to be.
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
— Humanigen, Inc. (@humanigen) June 9, 2023
Full Story: https://t.co/mXv7opGRkr
@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Medical
The identities of the owners of taran and hgenq is UNKNOWN and secret hidden in layers and layers of different bank accounts and beneficiaries like the ADR based in cayman islands. the papers or beneficiaries are secret too and not disclosed. nobody really knows who actually owns Taran or hgenq as the current 4 'employees' are just hired hands and front people. or the frontman of this operation. I know one guy who runs 10 stocks okay. or a few entities control the entire market.
What YOU don't understand is the design of the company's share structure, where company insiders were merely the nominee share holders. They held shares for the beneficial owner. Transactions reflecting buys and sells amongst Dale's entities, were actually just reflecting the transfer of shares between the entities.
what don't you understand, the company or entity who loan the shares loan the shares to another entity they own to short. in other words, the company loan the shares to themselves. like Taran also owns and controls hgenq the controlling shareholder...what you don't understand. why you think Taran got or won the ip assets of lenzi which say could be worth millions or billions. technically, Taran bought all the ip assets for FREE. as the book value says all of hgenq assets include LENZI was worth ZERO value. so they paid nothing for it technically speaking
The company provided the 'locates,' meaning they agreed to loan the shares. They have a right to recall those loaned shares. Brokers will be forced to buy-in their short sellers.
Because authorized shares was 250 million shares,
they could easily raise additional equity via share dilution or issuing more shares to raise capital to continue operations instead of going bankrupt. the lawsuits were fake and the company wanted to get sued so it declare chapter 11. and make equity worthless after selling over 100 million in equity in 2021 and 2022. after bankruptcy, the guy still owns the ip assets and investors who bought the shares get nothing and shares worthless. it's classic stock scam. that is a common theme in many companies. but its so obvious now. too obvious.
authorized shares is : 250,000,000 shares
outstanding shares: 119,080,135
shares held at DTC Depository Trust Corporation for trading: 36,460,494
shares still short: 38,497 as of may 31,2024 still short and not covered which is ridiculous.
makes the data unreliable and ask yourself --who would still be short in a bankrupt stock now?
DTC shares are shares sold to customers via brokerages
Where does Cowtown get the loan shares and recall?
unless he has other information that I don't have. there is no share recall. it could shares shorted naked and not in publicly available information. or swaps where or OTC counter contracts between parties. that the company has with the market makers of this ticker. either cowtown jay is dilusional about this ticker or has another thing coming.
retail accounts cannot short 100 million shares of many stocks as there is no shares to short or limited. and you have to pay your brokerage fees to short. lots of stock had no shares to short. to short shares, the buyer would have to borrow money or the shares are on margin for the broker to lend it out and shorter has to pay a short fee which discourages shorting for retail accounts as a result only professional or market makers can short naked as they don't have to pay shorting fees. so any cash you get from shorting you cannot collect interest on it.
that is why you still see millions of shares STILL Short or own loan and still not covered. the entity who still owns this stock or owns 110 million lent the shares to himself to short. once they shorted all their shares, they want to bankrupt the company and make it worthless and go bankrupt and don't have to cover and still own the company even though it was sold.
here is a stock tip:
the shares shorted WAS shorted by the owners of the company via another entity as short trade.
they sold all their shares SHORT and still own the shares. so they never have to cover yet still control 110 million shares and own the company even though they sold the company via shorting in 2021 with raising new equity. you think they would have covered right? it's one of the deep secrets of the market. or wall street and it involves co operation from the market maker of the exchange and market marker when it was still trading in nasdaq.
To me, part of the reason for investing here has always been a stock play, such they executed previously DBA Kalobios. Does this sound familiar?
"KaloBios has been surging since Shkreli bought a 70% stake in the company earlier in November, rescuing it from insolvency. The company had announced just a week earlier that it was winding down operations because it was running out of cash while developing two potential cancer drugs."
https://www.marketwatch.com/story/kalobios-short-sellers-facing-squeeze-as-ceo-shkreli-says-will-no-longer-lend-stock-2015-11-27
alternate source:
https://moxreports.com/kbio-infinity-squeeze/
I have seen no reason to think that the company will not achieve certain strategic objectives, associated with Australian regulatory approval to treat CMML, perhaps with the addition of Filip Dubovsky to work with our new entity and with the Sanofi spin-off. I also believe Humanigen may control ~90% of their Outstanding Shares.
But to be sure, we appear to be in a precarious situation. However, I just don't believe that we are. I will believe that until management tells us differently.
I do hope you are correct. From my extremely limited knowledge of chapter 11 proceedings, my understanding is that the treatment section for classifications is all but guaranteed. While I see the sections you quoted as well, I believe that's only if those of us that fall in class 5 receive a payout after the liquidation of the assets. Based on the asset disclosure it doesn't appear there is nearly enough $ to reach us. With that said, I could be very incorrect.
Tomorrow back at my desk I'd be happy to share the file cache link on the epiq website which contains all files since January.
Thank you, SorcererGuru44.
I see that the last sentence on page 38/70 still contains the following.
"Pursuant to the Combined Plan and Disclosure Statement, the Liquidating Trustee, in its sole discretion, may establish the Existing Equity Interests Record Date should there be a Distribution to Holders of Allowed Existing Equity Interests."
https://document.epiq11.com/document/getdocumentbycode?docId=4343564&projectCode=HUM&source=dm
The section for Treatment of Existing Equity Holders that you quoted also notes, a few paragraphs after the information you quoted, the following.
"Allowance: Existing Equity Interests held by Holders thereof as
of the Existing Equity Interests Distribution Record Date (which
such date may be established by the Liquidating Trustee in its sole
and absolute discretion) shall be Allowed Existing Equity
Interests under the Combined Plan and Disclosure Statement (as
reflected by DTC and/or the Debtor’s official register of holders
of common stock)."
I suspect there is going to be a significant difference in the number of shares reported by the DTC, versus the number of shares reported by the company's Transfer Agent.
We'll see how things transpire. It could get interesting if the company requests to have their shares in certificate form. However, you did source the material I was waiting for, and I very much appreciate your post.
Contrary to what I've been reading about myself, I am not paid to post. I've said that before, but it evidently bears repeating. I've also said repeatedly that I am retied, and living on a fixed income, and sometimes unexpected repairs, etc., have to be put off. So at the earliest possible time, if good news is on our horizon, I want to hear it. My open sell orders will expire in about two weeks. As I look at the pieces that have to be put into play for our success, I'm seeing what think are key components coming together. I know that lenz will be hugely successful, and I want to see existing equity holders, including management, receive the reward we deserve.
Once again, thank you for sourcing the important information you provided. Well done!
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43428
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |